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671). The mean annual overall direct health care cost for using lactate-based bal-
anced solution was estimated to be 2.16 billion rubles ($40.3 million), and for using 
acetate-based balanced solution - 2.05 billion rubles ($38.3 million). The CMA has 
shown that annual savings when used as a balanced infusion therapy acetate-based 
solution will be 110 million rubles ($ 2.05 million). ConClusions: The using for 
infusion therapy acetate-based balanced solution Jonosteril® was more economi-
cally justified treatment option.
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objeCtives: Despite concerns about interchangeability and substitution of bio-
similar products with reference products, they provide cost savings either by 
leading price reductions or increase in discounts of reference products. There 
are several studies demonstrating the actual/potential cost saving effects of bio-
similars. In this regard, the aim of this study is to define the price reductions 
or increase in discounts of reference products by the reimbursement of their 
biosimilars in Turkey. Methods: Biotechnology products, which are still avail-
able in the market, are selected from the list of pharmaceutical products pub-
lished on the Ministry of Health’s web site. Their registration dates and ex-factory 
prices and statuary discounts between 2009 and 2014 are searched. Afterwards, 
the change in the reference products’ ex-factory prices and statuary discounts 
is analyzed for the first year that biosimilar products are reimbursed. Results: 
Not considering the different forms of drugs there are 80 biotechnology products 
(66 active ingredients) being marketed in Turkish pharmaceutical market. 10 of 
them are biosimilar products (7 active ingredient). The first biotechnology product 
and the biosimilar product were registered in Turkey in 1992 and 2009 respec-
tively. Only 4 active ingredients have both biosimilar and the reference product. 
By the reimbursement of the biosimilar products, the statuary discount of all 
the reference products increased between %14 and %113 and the price of the 2 
reference product decreased by %26 and %31 while the prices of other products 
didn’t change. ConClusions: Depending on the analysis bio-similars may have 
a cost-reduction impact on pharmaceutical budgets. Further analysis should be 
conducted on the reason of price reductions of reference products by penetration 
of biosimilars whether by leading direct reductions or increased discounts in order 
to exempt the effect or general pricing regulations or cost containment measures 
unlikely to be specific to biotechnology products.
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objeCtives: To understand how EU healthcare decision makers define value when 
assessing biosimilar treatments Methods: Combination of desk research to track 
current biosimilar market trends, followed by qualitative research including one-to-
one interviews with six EU sub-national payers and key opinion leaders. Results: 
European payers consider more than just list and net prices when purchasing and 
supplying novel biosimilar treatments for patients. Whilst payers do consider key 
aspects such as product attributes in the decision making process, it is economic 
and public health benefits, supply chain quality, reputation of the manufacturer, 
national guidance, support and demand from key units or physicians within their 
region, that remain as the most influential factors in the decision making pro-
cess. ConClusions: Many EU payers still consider value beyond just price of a new 
medicine. However, recent biosimilar launches in the Nordics are challenging this 
paradigm and affecting discount expectations on biosimilars vs. original compounds 
in western EU countries. While sub-national payers need to ensure that biosimilar 
medicines can be supplied to their patients at a consistent level of quality and quan-
tity, biosimilar manufacturers need to ensure new compounds are launched into 
the market, at suitable price, with a successful commercial strategy that includes 
dedicated sales and marketing efforts. Moving forward, it will be important for bio-
similar manufacturers to understand what payers, physicians and patients value 
within a new medicine before entering price discussions.
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objeCtives: In Brazil, law regulates the use of human albumin and divide recom-
mendations into formal, questionable and unsubstantiated. The aim was to verify 
compliance with the requirements of this medicine in relation to national guidelines 
and calculate the costs of unsubstantiated indications of human albumin 20%, 
at a public hospital. Methods: We evaluated the records of patients who used 
human albumin 20% during hospitalization at a public hospital in the period from 
August, 2013 to August, 2014. There were no restrictions as patient age or duration of 
therapy. Quantitative variables were expressed as by mean and standard deviation, 
and not quantitative variables in by absolute and relative frequency. Results: We 
evaluated the records of 63 patients with a mean age of 60.6 ± 71.8 years. Most of 
them were men (40; 64.5%). Length of stay was 30.0 ± 47.2 days. Duration of albu-
min therapy was 6.0 ± 6.7 days (mean). Average total cost was US $ 174.13 ± 195.10 
per patient. Nineteen (30.2%) of albumin indication was classified as questionable 
and 15 (23.8%) as unsubstantiated. Cost of unsubstantiated indications was US $ 
2,379.80/year or US $ 158.65/patient, this represents 21.7% costs of albumin during 
the study period. Unsubstantiated indications were: use in intensive care (12; 19.0%), 
fluid replacement in acute losses (2; 3.2%) and hypoalbuminemia in patients with 
Suppliers were also observed to charge different prices for the same brands to 
different public hospitals, indicating information asymmetry on reasonable prices 
of drugs. ConClusions: Based on the observed wide variations in drug procure-
ment prices in the Philippines, setting the DPRI at the median value for most 
drugs was found to be an appropriate method to set ceiling prices for public sector 
procurement. For monopolized pharmaceutical products, other methods may be 
more appropriate such as value-based pricing, price negotiations and external 
reference pricing to relevant countries.
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objeCtives: To work out the cost-benefit analysis (CBA) of the infrastructural devel-
opment major project of Jósa András Teaching Hospital (Nyíregyháza, Hungary) 
funded by EU grants. Two supported projects (complex hospital development and 
an integratedemergency care unit) were merged and had to be revised according 
to the major project requirements because of the recent significant cost increases. 
At the end of 2014 the project in value of 56.15 million EUR was submitted to the 
European Commission. Methods: The CBA was based on the guidelines outlined 
in the EU Regional Policy and concerning Working Document. A 25-year time horizon 
was determined . 5% financial and 5.5% social discount rate were applied, as recom-
mended in the guidelines. Analyses were conducted using the incremental method 
considering Business as usual and Project scenario. To express the monetary value 
of socio-economic benefits we applied the willingness-to-pay method. The value of 
24,772 EUR was used as an average value of human life year based on the published 
data (EuroVaq) regarding the Hungarian population. Aggregating socio-economic 
benefits, we considered the monetized values of the following health gains: reduc-
tion in the 30-day AMI death rate, in county cancer deaths, in infant mortality, in 
the number of registered people with permanent disabilities, in lost income and 
health gain attainable through improving the quality of care. Results: Financial 
net present value (-50.6 million EUR), economic net present value (27.3 million EUR), 
financial rate of return (-8.15%), economic rate of return (9.44%) and cost-benefit 
ratio (1.62) were calculated as results of CBA. ConClusions: The CBA reflected the 
fact that health care investments in the public sector are not directly financially 
recovered for the owner, but - considering the broader socio-economic effects - the 
project meets the requirement that the level of socio-economic benefits are higher 
than the socio-economic costs.
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objeCtives: The shorter the response time of emergency services the more lives are 
saved. But, how important in fact is the time factor for saving lives? The objective of 
this study is to analyse the relation between response time and fatalities, to be able 
to measure how many lives could be saved with a shorter response time. Methods: 
The study uses data from reports from the fire and rescue services in Sweden for 
2005–2013 for residential fires. The time variable used is continuous and the sta-
tistical methods are non-linear regression techniques. Results: It is found that 
the risk of fatality is a non-linear function of response time. The marginal effect 
of response time is first large, then decreases, and eventually seems to approach 
zero. If it was possible to decrease the median response time by one minute 0.00035 
lives could be saved for every turn-out. For all turn-outs to residential homes that 
means that about two lives, or 3%, could be saved per year. The response time 
is most important for blocks of flats, nursing homes and semi-detached/terraced 
houses. The response time is more important for fires due to smoking, children 
playing or started intentionally (arson). ConClusions: The results can be used to 
evaluate the performance of local fire and rescue services. It can also be used as a 
planning tool for fire and rescue services when it comes to the importance of dif-
ferent causes of injuries. The method is easy to use for other emergency services, 
such as ambulances.
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objeCtives: The main aim of this study was to conduct a comparative phar-
macoeconomic analysis of the using 2 variants of balanced crystalloids infusion 
therapy – acetate- (Jonosteril®) and lactate-based (Sterofundin ISO®). Methods: 
Analysis of the published clinical trials was conducted to evaluate comparative 
efficacy and safety of using balanced solutions of different composition. Direct 
medical costs for using 2 variants of balanced infusion therapy were calculated. 
Taking into account the hypothesis of equal effectiveness of balanced solutions of 
different compositions for pharmacoeconomic analysis was chosen “cost minimi-
zation” analysis (CMA). To calculate the direct costs of infusion therapy was deter-
mined the average duration of infusion therapy in patients with traumatic shock 
conditions in the intensive care unit on the basis of the actual practice of the N.V. 
Sklifosovsky Research Institute of Emergency Care. Direct costs were included the 
cost of one day of application infusion therapy on the basis of 2000 ml per day for 1 
patient. Results: According to published trials the using of different combinations 
of crystalloids such as acetate- and lactate-based were provided equal hemody-
namic stability. The average cost of a course of infusion therapy in patients with 
traumatic shock conditions by using acetate-balanced based solution was 34 104 
rubles ($ 636.8), and by using lactate- based balanced solution - 35 936.8 rubles ($ 
